A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer

Inclusion Criteria:

* Age \>=18 years
* For paclitaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease
* For docetaxel combination arms: histologically or cytologically documented adenocarcinoma of the breast with locally recurrent or metastatic disease or histologically documented advanced (Stage IV) or recurrent NSCLC
* For participants with breast cancer: HER2-negative disease as defined by local clinical guidelines
* Participants with NSCLC to be treated with docetaxel need to have received at least one prior anti-cancer treatment regimen in an advanced setting and to have docetaxel be considered appropriate treatment
* Evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) v.1.1
* Life expectancy \>=12 weeks
* Eastern cooperative oncology group (ECOG) performance status of 0 or 1 at screening
* Adequate hematologic and end organ function
* Use of highly effective form of contraception

Exclusion Criteria:

* Prior anti-cancer therapy
* Prior treatment with phosphoinositide 3-kinase (PI3K) inhibitor
* Known significant hypersensitivity to any components of study treatment
* Grade \>=2 peripheral neuropathy
* Type 1 or Type 2 diabetes
* Grade \>=2 hypercholesterolemia or hypertriglyceridemia
* Congenital long QT syndrome
* Active congestive heart failure or ventricular arrhythmia